Icon,a global provider of outsourced development services, is expanding its U.S. and U.K. bioanalytical facilities to meet the growing demand for biomarker and cell-based assay services.

Icon has increased its bioanalytical laboratories in Whitesboro, N.Y., and Manchester, U.K., by 7,000 and 4,000 square feet, respectively. The expansions allow Icon to house dedicated immunoassay laboratories at each facility for biomarker testing and cell-based assays.

“We have expanded our bioanalytical facilities to provide the necessary scale to support the ever-broadening range of testing services required by our sponsors,” said Brian O’Dwyer, senior vice president of global bioanalytical services, development solutions, Icon. “In particular, the expansion of our dedicated biomarker testing laboratories allows us to support biomarker development programs across multiple testing platforms globally.”

Operating since 1988, Icon’s Whitesboro facility already features multiple wet laboratories and instrument laboratories for small and large molecules, including a specially designed hazardous lab for the analysis of HIV and hepatitis B infected samples. Similarly, Icon’s Manchester laboratory has provided bioanalytical support for both small and large molecule studies for almost 30 years and is located close to Icon 's hospital-based clinical pharmacology unit in Manchester.